# A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

> **NCT02629159** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 1629 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo for Adalimumab
- **DRUG:** Adalimumab
- **DRUG:** Placebo for Upadacitinib
- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT02629159
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-12-01
- **Primary completion:** 2017-10-27
- **Final completion:** 2027-09-30
- **Target enrollment:** 1629 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02629159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02629159, "A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02629159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*